Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

sign that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent.

CUSTOM I and II Webcast and Slide Presentation

As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM I and CUSTOM II data at 7:00 a.m. EDT on Monday, October 22. The public can access the webcast via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm, or by calling 888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in or access the Web site five to ten minutes prior to the beginning of the call. The webcast will be archived on the Web site for a minimum of three months, and can be accessed at the investor relations portion of the company's Web site at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... EXTON, Pa., Aug. 18, 2011 Kensey Nash Corporation (NASDAQ: ... on regenerative medicine for a wide range of medical procedures, ... year ended June 30, 2011.   Fourth ... earnings per share of $0.34, which includes net Norian acquisition ...
... MEDFORD, N.Y., Aug. 18, 2011 Richard Larkin, Chief Financial ... develops, manufactures, markets and licenses point-of-care diagnostic tests, is among ... from Long Island Business News ( LIBN ). ... year.  Among the honorees, Mr. Larkin was one of two ...
Cached Medicine Technology:Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 2Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 3Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 4Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 5Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 6Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 7Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 8Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 9Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 10Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 11Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 12Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 13Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 14Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 15Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 16Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 17Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 18Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 19Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 20Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results 21Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 2Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 3
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... years, especially women, are less likely to face the ... researchers say. But regular exercise while young only ... about 150 minutes of moderate to vigorous physical activity ...
... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
... 14, 2010 Researchers at UT Southwestern Medical Center ... and normal tissue that predict survival time and potential ... "Patient responses to cancer treatment vary widely and ... Dr. David Mangelsdorf, chairman of pharmacology at UT Southwestern ...
... weapon against inoperable liver cancer is so tiny that ... to interventional radiologists at the Indiana University School of ... The glass spheres contain a radioactive element, yttrium-90, ... a very limited distance so that healthy tissue around ...
... Pallarito HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay ... a key component of the new U.S. health-care reform law ... the first successful challenge to the controversial legislation. ... President Barack Obama and fellow Democrats against Republicans, will continue ...
... -- Scientists report that they have advanced their knowledge ... identifying 13 new potential variations. Tumors called pheochromocytomas ... the kidney. These tumors -- which are usually benign ... gland to produce too much adrenaline, resulting in high ...
Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
Medicine Products: